Cytochrome P450 enzymes are a large family of heme-containing oxidases that catalyze the oxidative metabolism of many endogenous compounds and roughly half of clinically used drugs. Peter R. Guengerich, Vanderbilt University Medical Center, has reviewed how these enzymes introduce or expose polar functional groups through reactions such as hydroxylation, epoxidation, and N- or O-dealkylation, transforming lipophilic drugs into more water-soluble metabolites that are then substrates for conjugation and renal or biliary excretion. By altering molecular structure, CYPs directly influence a drug’s half-life, active concentrations, and the balance between therapeutic effect and toxicity.
Mechanisms of CYP-mediated metabolism CYP enzymes perform Phase I metabolism, often creating sites for Phase II conjugation by transferases. Different CYP isoforms have distinct substrate specificities. CYP3A4 is among the most abundant hepatic and intestinal isoforms and metabolizes a large fraction of prescription drugs. CYP2D6, CYP2C9, CYP2C19, CYP1A2, and CYP2E1 are other clinically important families. The site of expression matters: intestinal CYP3A4 can limit oral bioavailability, while hepatic enzymes govern systemic clearance. Genetic variation, co-administered drugs, diet, smoking, inflammatory states, and liver disease can modify expression or activity, changing metabolic outcomes.
Clinical, genetic and environmental consequences Genetic polymorphisms in CYP genes produce phenotypes ranging from poor to ultrarapid metabolizers. For example, CYP2D6 gene duplications can create ultrarapid metabolism that converts prodrugs into active forms quickly, increasing the risk of toxicity, whereas loss-of-function alleles reduce conversion and may cause therapeutic failure. The U.S. Food and Drug Administration has issued warnings about codeine use in children due to variable CYP2D6-mediated activation to morphine. Clinical Pharmacogenetics Implementation Consortium at St. Jude Children's Research Hospital provides genotype-based prescribing guidance that illustrates how genotypes inform dosing decisions for many CYP substrates.
Drug-drug and drug-food interactions CYPs are frequent sites of drug-drug interactions because some compounds inhibit enzyme activity while others induce expression. Strong inhibitors of CYP3A4, including certain antifungals and macrolide antibiotics, can markedly raise plasma levels of co-administered CYP3A4 substrates and cause adverse events. Conversely, inducers such as rifampicin or the herbal supplement St. John’s wort increase enzyme expression and can lower drug concentrations, risking loss of efficacy. Food constituents also matter: grapefruit juice contains furanocoumarins that inhibit intestinal CYP3A4 and can increase oral exposure to several medications. Smoking induces CYP1A2, altering the metabolism of drugs like clozapine and olanzapine.
Population and territorial nuances The prevalence of specific CYP alleles varies by population, shaping regional patterns of drug response and safety. CYP2C19 loss-of-function alleles are more common in East Asian populations, affecting the efficacy of drugs such as clopidogrel and certain antidepressants, while CYP2D6 ultrarapid metabolizer alleles are relatively more frequent in some North African and Middle Eastern groups. These population differences underscore the importance of integrating genetic, cultural, and environmental information into prescribing decisions to reduce adverse reactions and improve therapeutic outcomes.